COMPLEMENT AND LDL

COMPLEMENT AND ATHEROSCLEROSIS: MOLECULAR MECHANISM OF C1 ACTIVATION BY ENZYMATICALLY MODIFIED LOW-DENSITY LIPOPROTEINS

Coordinatore	CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE    more  Organization address address: Rue Michel -Ange 3 city: PARIS postcode: 75794 contact info Titolo: Dr. Nome: Jean-Xavier Cognome: Boucherle Email: send email Telefono: -76887895 Fax: -76881145
Nazionalità Coordinatore	France [FR]
Totale costo	171˙600 €
EC contributo	171˙600 €
Programma	FP7-PEOPLE Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	FP7-PEOPLE-2007-2-1-IEF
Funding Scheme	MC-IEF
Anno di inizio	2008
Periodo (anno-mese-giorno)	2008-05-01   -   2010-04-30

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE  Organization address address: Rue Michel -Ange 3 city: PARIS postcode: 75794 contact info Titolo: Dr. Nome: Jean-Xavier Cognome: Boucherle Email: send email Telefono: -76887895 Fax: -76881145	FR (PARIS)	coordinator	0.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Atherosclerosis is considered to be a chronic inflammatory process. Arterial inflammation that precedes plaque development is caused by accumulation of LDL (low density lipoproteins) in the extracellular matrix of the vessels. These LDL particles are modified by a number of processes, including enzymatic degradation, aggregation and oxidation. Complement is also emerging as an important factor in this process: complement activation and formation of the terminal C5b-9 membrane attack complex were shown to occur in atherosclerotic lesions. Recently we have studied the ability of enzymatically modified LDL (E-LDL) to activate C1, the complex that triggers the classical pathway of complement. E-LDL is recognized by the C1q subunit of C1 and triggers direct C1 activation, suggesting that complement activation by E-LDL may play a crucial role in the pathogenesis of atherosclerosis. The objective of this proposal is to characterize the mechanisms involved in the recognition of E-LDL by C1q. We aim at (i) identifying the molecules recognized by C1q; (ii) characterizing the molecular mechanisms involved in this recognition; and (iii) analyzing the mechanisms underlying E-LDL-mediated C1 activation. The project is based on approaches at the molecular and structural levels, and will involve protein biochemistry methods, X-ray crystallography, surface plasmon resonance spectroscopy and functional studies. From a fundamental standpoint, the immediate benefit of this work will be to improve our knowledge of the mechanisms that allow C1q to act as a “sensor” of altered self structures. The biomedical applications of our results could have a considerable impact in the development of new therapeutic strategies against atherosclerosis, because the molecular mapping of the interaction between E-LDL and C1q could help design and synthesize molecules able to interfere with this interaction and thereby to control or prevent complement activation.'

Introduzione (Teaser)

Atherosclerosis, hardening of the arteries, takes place through a chronic inflammatory process. Inflammation of the arteries is caused by a build-up of low-density lipoproteins outside cells in the blood vessels, eventually leading to plaque development.